Navigation Links
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics

Strategic deal demonstrates commitment to dermatology and innovation

CORAL GABLES, Fla., Aug. 6 /PRNewswire/ -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, announced today that it has completed its previously announced acquisition of Princeton, New Jersey-based Barrier Therapeutics, Inc. Upon the closing of the acquisition, all remaining outstanding shares of Barrier common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law, were converted into the right to receive $4.15 per share in cash. Effective with the close of trading on August 6, 2008, shares of Barrier will no longer be listed on the NASDAQ Global Market.

The combination of Barrier Therapeutics with Stiefel Laboratories unites some of the most exciting assets in the dermatology industry. The acquisition of Barrier broadens Stiefel's extensive product offering with three premium prescription products, making a wider range of treatment options available to physicians and patients under the Stiefel umbrella. It also deepens an already strong Stiefel pipeline of products by adding several promising novel product candidates.

"Barrier's innovative products and pipeline are a very valuable addition to Stiefel," said Charles W. Stiefel, chairman and chief executive officer, Stiefel Laboratories. "The acquisition reinforces Stiefel's promise to provide novel, high-quality, safe and effective products for the treatment of skin diseases and our continued and enthusiastic commitment to advancing the field of dermatology."

In addition to bringing new assets to Stiefel, the acquisition also provides the opportunity for the company to leverage its global footprint for the newly-acquired portfolio.

"Stiefel's worldwide network includes more than 30 subsidiaries around the world, a research and development organization spanning four continents and six manufacturing operations," said Bill Humphries, president, Stiefel Laboratories. "Combining these resources with Barrier's products will benefit more dermatology patients around the world."

"The acquisition greatly expands the possibilities for Barrier's products and pipeline," said Al Altomari, chief executive officer of Barrier Therapeutics. "We are excited about the contributions that can be made in dermatology because of this transaction."

"The product portfolio and pipeline we have created with this acquisition further solidifies Stiefel's position as the worldwide leader in dermatology," Humphries said, "and continues to help us achieve our goal of becoming the most-respected dermatology company in the world."

The Global Headquarters of Stiefel Laboratories will remain in Coral Gables, Fla., and the Marketing and Sales headquarters will remain in Duluth, Ga.

About Barrier Therapeutics

Barrier Therapeutics is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(R) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections.

Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%) available in the Duac(R) Care System (CS); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, 0.05% and Olux-E(R) (clobetasol propionate) Foam, 0.05% also available in the Olux(R) / Olux-E(R) COMPLETE PACK; Soriatane(R) (acitretin) Capsules available in the Soriatane(R) CK CONVENIENCE KIT; Verdeso(R) (desonide) Foam, 0.05%; Brevoxyl(R)-4 Creamy Wash (benzoyl peroxide 4%) and Brevoxyl(R)-8 Creamy Wash (benzoyl peroxide 8%) packaged in the Brevoxyl(R) Acne Wash Kit; Extina(R) (ketoconazole) Foam, 2%; Oilatum(R) Cleansing Bar; Physiogel(R) Cream; Stieprox(R) (ciclopirox olamine) Shampoo; REVALESKIN(TM) Skin Care Products; and Sarna(R) Lotion. Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit

SOURCE Stiefel Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
2. Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development
3. Stiefel Laboratories Appoints First Chief Scientific Officer
4. Stiefel Laboratories, Inc. Appoints New President
5. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
6. ARUP Laboratories and Weber State University Announce Educational Collaboration
7. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
8. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
9. Mesa Laboratories, Inc. Named to Fortune Small Business Magazines 2008 List
10. SpectraCell Laboratories Offers Additional Test for Heart Attack and Stroke Risk
11. Mesa Laboratories, Inc. Added to the Russell Microcap Index
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant ... coding changes are likely to include new codes for spine and hip X-rays, ... understand the effects of code changes in musculoskeletal, radiology and nervous system sections ...
(Date:11/30/2015)... TX (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced the ... $11.95 each. Available in a choice of three different colors; red ( NSP-1632 ), yellow ... each run up to 18 hours in constant-on mode, or 27 hours in blinking strobe ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas ... Sublime Beauty NATURALS®. All products are available on Amazon or its webstore. , ... facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... 2015  Hanger, Inc. (NYSE: HGR ) (the ... terms of its previously announced consent solicitation (as amended ... aggregate principal amount 7⅛% Senior Notes due 2018 (the ... fees payable pursuant to the Consent Solicitation, (ii) the ... the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
Breaking Medicine Technology: